Sunday, August 23, 2026
21 C
Bengaluru

Analysis of the Fastest Growing Companies and Therapy Areas in IPM – MAT Dec’24

  1. Growth Performance of Top 50 Companies in IPM (MAT Dec’24)

The top 50 pharmaceutical companies in the Indian Pharmaceutical Market (IPM) have grown significantly in various zones (West, South, North, and East). The following key insights emerge:
The top 30 cities contributed 34% to IPM Sales for MAT Dec’24.
• The top cities grew at 8.5%, slightly higher than the overall IPM growth of 7.6%.
• Among mega metros, Delhi was the fastest-growing at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).
• Fastest-growing cities: Pune, Agra, Lucknow, Nashik, and Delhi saw the highest growth in demand.
• 13 out of the top 30 metros grew faster than the overall IPM, while 17 metros had growth equal to or lower than 7.6%.
• Reliance Life Sciences, Fresenius Kabi, and Merck Specialities were the fastest-growing in different regions, with growth rates exceeding 30-40%.

  1. Top 20 Fastest-Growing Companies by Zone

Each region showed distinct trends in terms of growth and key players:
• West Zone: AstraZeneca (28.6%), La Renon Healthcare (23.0%), Samarth Pharma (20.8%)
• South Zone: Reliance Life Sciences (47.6%), Fresenius Kabi (42.3%), Merck Specialities (30.9%)
• North Zone: AstraZeneca (37.7%), Bayer Pharma (33.9%), Aareen Healthcare (28.7%)
• East Zone: Hetero Healthcare (19.4%), Natco Pharma (18.9%), Corona Remedies (14.8%)

  1. Therapy Area Focus of the Fastest-Growing Companies

The fastest-growing pharmaceutical companies are focused on key therapy areas shaping healthcare’s future.

Company Key Therapy Focus Areas
1. AstraZeneca — Oncology, Respiratory, Cardiovascular, Diabetes
2. La Renon Healthcare — Nephrology, Critical Care, Gastroenterology
3. Samarth Pharma — Critical Care, Oncology, Neurology
4. Nutricia (Danone) — Pediatric & Medical Nutrition
5. IPCA Labs — Pain Management, Anti-Malarial, Dermatology, Cardiovascular
6. Reliance Life Sciences — Biosimilars, Oncology, Critical Care, Fertility
7. Fresenius Kabi — Oncology, Critical Care, Parenteral Nutrition
8. Merck Specialties — Oncology, Immunology, Cardiovascular, Diabetes
9. Hetero Healthcare — Antivirals, HIV/AIDS, Oncology, Biosimilars
10. Sun Pharma — Dermatology, Oncology, Cardiology, Psychiatry, Gastroenterology
11. Dr. Reddy’s Laboratories — Generics, Oncology, Neurology, Gastroenterology, Biosimilars
12. Glenmark Pharma — Respiratory, Dermatology, Oncology, Cardiology
13. Bayer Pharma — Cardiology, Women’s Health, Oncology
14. Torrent Pharma — Cardiovascular, CNS, Gastrointestinal, Diabetes
15. Zydus Cadila — Vaccines, Oncology, Pain Management, Diabetes, Neurology
16. Natco Pharma — Oncology, Neurology, Hepatitis C, Cardiology
17. Ajanta Pharma — Dermatology, Ophthalmology, Cardiology, Pain Management

  1. Key Trends in Therapy Areas
    1. Oncology Dominance:
      • AstraZeneca, Merck, Reliance Life Sciences, Fresenius Kabi, and Natco Pharma have a strong presence in cancer treatment, reflecting global trends in high-value specialty drugs.
    2. Cardiovascular & Diabetes Growth:
      • AstraZeneca, Bayer, and Torrent Pharma are investing heavily in cardiology and diabetes due to the rising burden of lifestyle diseases.
    3. Biosimilars & Specialty Therapies:
      • Hetero Healthcare, Reliance Life Sciences, and Dr. Reddy’s are actively working on biosimilars, targeting biologic drug demand.
    4. Critical Care & Nephrology Focus:
      • La Renon Healthcare, Samarth Pharma, and Fresenius Kabi are leading in hospital-based critical care, parenteral nutrition, and renal therapies.
    5. Respiratory & Dermatology Demand:
      • Glenmark Pharma and Sun Pharma continue to dominate dermatology and respiratory segments, driven by asthma/COPD and skincare demand.

Conclusion
• Strong Growth in Pharma Market: The top companies and metros have outperformed the overall IPM growth rate, indicating high market demand.
• Oncology, Cardiovascular, and Specialty Biologics Lead: Companies with a strong focus on oncology, diabetes, and specialty therapies are well-positioned for long-term growth.
• City-Wise Demand Varies: While metros like Delhi, Chennai, and Hyderabad are leading growth, emerging cities like Pune, Agra, and Nashik are key expansion markets.

With the rising demand for chronic disease treatments, biosimilars, and specialty care, pharmaceutical companies investing in oncology, diabetes, and biosimilars will likely drive the next wave of industry growth.

Hot this week

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Topics

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...
spot_img

Related Articles

spot_imgspot_img